Article

Don't forget to wash your hands

Resistant bacterial organisms, such as methicillin-resistant Staphylococcus aureus (MRSA), are a major problem for our hospital-based colleagues and their patients. And the problem is getting worse. Because ophthalmology is an outpatient specialty, with many procedures performed either in office or at ambulatory surgery centers, ophthalmologists may have considered themselves relatively unaffected by that trend. Overwhelmingly, however, the data pour in to tell us that MRSA is no longer a hospital problem, but a community problem.

Key Points

"We are well on the way towards getting rid of the harmful bacteria and viruses causing disease, and it is probable that most of those we suffer from will be merely historical curiosities in the next century."

-James Harpole, "Leaves from a Surgeon's Case-Book" F.A. Stokes Co., 1937, page 202

Because ophthalmology is an outpatient specialty, with many of our procedures performed either in office or at ambulatory surgery centers, we ophthalmologists may have considered ourselves relatively unaffected by that trend. Overwhelmingly, however, the data pour in to tell us that MRSA is no longer a hospital problem, but a community problem.

According to the CDC study, "Despite the increase in MRSA prevalence, there was also a decrease in MRSA that was resistant to multiple drugs. The researchers hypothesize that the influx of MRSA strains from the community might have replaced those multidrug-resistant strains associated with the hospital. 'Unlike traditional MRSA the community strain is very fit-it causes infection in healthy people,' said CDC epidemiologist R. Monina Klevens, DDS, MPH. 'When it is introduced into a hospital, where ill patients are more vulnerable to infection, it has the potential to cause significant morbidity and mortality.' Due to community MRSA's ability to infect the young and healthy, traditional risk factors for identifying hospital-associated MRSA colonization, such as dialysis and prior hospitalization, are not effective predictors of whether a person is carrying the community strain."

Researchers at the Monroe Carell Jr. Children's Hospital at Vanderbilt University, Nashville, TN, swabbed the noses of 500 healthy children who were at their pediatricians' office for routine immunizations.2 In 2002, 1% of children had the bacteria in their noses. In a follow-up study 2 years later, 9.2% had the bacteria.

"What we see now is a germ that is firmly entrenched in the community," said Buddy Creech, MD, MPH. "Children really don't have to have any risk factors for having these bacteria. They don't have to be sick, and they don't have to have had antibiotics recently."

More than half of the Staphylococcus skin infections seen in the university's emergency room are caused by MRSA. The figure puts Nashville in line with cities such as Chicago and Houston that have a higher-than-average frequency of the bacteria, he said. According to a 2005 CDC study, about 2 million people carry MRSA in their noses.3

In 2003, 10% of a Connecticut college's football team contracted MRSA infections. Two players had to be hospitalized.

Athletes who practiced body shaving had a 43% risk of MRSA infection, and players who sustained turf burns on the artificial turf field were seven times more like to come down with an MRSA infection.4 More than half of all athletic trainers have treated athletes for skin infections caused by MRSA.5

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.